Life Science & Biotechnology Archives - Page 2 of 5

12th Dec 2018

Case Note: H Lundbeck A/S & Anor v Sandoz Pty Ltd

A recent decision of the Federal Court of Australia has demonstrated that the launch of a pharmaceutical product by a generic company even after expiry of the standard term...

A recent decision of the Federal Court of Australia has demonstrated that the launch of a pharmaceutical product by...

13th Nov 2018

Sigma Pharmaceuticals Case Clarifies Aspects of Compensable Loss

The recent decision in Sigma Pharmaceuticals (Australia) Pty Ltd v Wyeth FCA 1556 has clarified, among other things, a number of issues concerning compensation arising from the usual...

The recent decision in Sigma Pharmaceuticals (Australia) Pty Ltd v Wyeth FCA 1556 has clarified, among other things,...

24th Oct 2018

Extension of Term for Pharmaceutical Patents in Australia – Overview and Recent Developments

The Australian Patents Act (the Act) has provisions for extending the term of standard patents which relate to pharmaceutical substances. These provisions are based on the premise that a...

The Australian Patents Act (the Act) has provisions for extending the term of standard patents which relate to pharmaceutical...

24th Sep 2018

Malaysia Update – Matters Originating from Registrar of Trade Marks End at the Court of Appeal

The appellant, an international pharmaceutical company, filed a notice of opposition before the Registrar under section 28 of the Trade Marks Act 1976 ('the TMA') against the respondent’s application...

The appellant, an international pharmaceutical company, filed a notice of opposition before the Registrar under section 28 of the...

22nd Jun 2018

First interlocutory injunction granted in Australia restraining the threatened launch of a biosimilar

On 12 June 2018, Justice Burley of the Federal Court of Australia granted the first interlocutory injunction to restrain the threatened launch of a biosimilar pharmaceutical product in Australia,...

On 12 June 2018, Justice Burley of the Federal Court of Australia granted the first interlocutory injunction to restrain...

13th Nov 2017

Australia Update: Swiss style claims and patent term extension

Under Australian patent law, the term of a pharmaceutical patent may be extended if certain criteria are met. In this regard, a patent term extension (PTE) of up to...

Under Australian patent law, the term of a pharmaceutical patent may be extended if certain criteria are met. In...

31st Aug 2017

Commonwealth of Australia v Sanofi: Hearing of Commonwealth’s Claim Commences in Federal Court of Australia

A six-week hearing in the Federal Court of Australia commenced this week to decide whether the Commonwealth is entitled to damages related to generics being delayed from listing on...

A six-week hearing in the Federal Court of Australia commenced this week to decide whether the Commonwealth is entitled...

31st Aug 2017

Protection of Second and Subsequent Medical Use in Singapore

In Singapore, second and subsequent medical use of a known substance has traditionally been claimed as Swiss-style claims which take the form of “Use of compound X in the...

In Singapore, second and subsequent medical use of a known substance has traditionally been claimed as Swiss-style claims which...

18th Aug 2017

Australia Update: Patent Term Extensions Not Available on the Basis of Swiss-style Claims

AbbVie Biotechnology Ltd v Commissioner of Patents AATA 682 has been overturned. Today, the Full Federal Court set aside a decision of the Administrative Appeals Tribunal thereby making...

AbbVie Biotechnology Ltd v Commissioner of Patents AATA 682 has been overturned. Today, the Full Federal Court set...

3rd Aug 2017

Menarini Industrie Farmaceutiche Riunite S.r.l. [2017] NZIPOTM 5 (8 February 2017)

Menarini Industrie Farmaceutiche Riunite S.r.l (“Menarini”) applied to register the mark KETUM in relation to an“anti-inflammatory drug used to ease joint and muscle pain” in class 5.

Menarini Industrie Farmaceutiche Riunite S.r.l (“Menarini”) applied to register the mark KETUM in relation to an“anti-inflammatory drug used to...

2nd Aug 2017

Patentability of Known Technology

For a product or process to be patentable in Australia, it is commonly understood that it must be novel (new), possess an inventive (non-obvious advantage over similar technology) and...

For a product or process to be patentable in Australia, it is commonly understood that it must be novel...

8th Jun 2017

Plant IP Protection in Australia: Patent, Plant Breeder’s Rights, or both?

In Australia, plant varieties, including genetically modified plants, can be protected under both the Australian Plant Breeder's Rights Act 1994 (the “PBR Act”) and the Australian Patents Act 1990....

In Australia, plant varieties, including genetically modified plants, can be protected under both the Australian Plant Breeder's Rights Act...